4.4 Skin Cancer Recognition, ABCDE Screening & Medical Contraindications

Skin Cancer Recognition, ABCDE Screening & Medical Contraindications

Continues from §4.3, “Melanocyte Biology & Pigmentation Disorders”. Recommending that a client seek a medical opinion is its own exam sub-topic. This section covers actinic keratosis and the three principal skin cancers, the ABCDE screening rule, and the contraindications that require a service to be declined and a referral made.

---

1. Cutaneous Malignancies & Precancerous Lesions

Skin cancers represent the most common type of malignancy diagnosed in the United States. Chronic and acute ultraviolet radiation exposure (both UVA and UVB) induces direct DNA pyrimidine dimer mutations and suppresses local cutaneous immune surveillance. Estheticians must understand the distinct pathology of precancers and the three major skin malignancies:

Cutaneous Neoplasm Spectrum:
├── Actinic Keratosis (Precancerous intraepidermal keratinocyte dysplasia ──> 10% risk of SCC)
├── Basal Cell Carcinoma (~80% of all skin cancers | Basal layer | Pearly nodule, rolled border, telangiectasia)
├── Squamous Cell Carcinoma (~20% of skin cancers | Squamous stratum spinosum | Crusted scaly plaque, ulcer)
└── Malignant Melanoma (~1-2% of skin cancers, >75% of skin cancer deaths | Melanocytic | Highly metastatic)

Actinic Keratosis (Solar Keratosis)

• Pathology: A common precancerous neoplasm of the epidermis consisting of atypical, dysplastic keratinocytes confined to the lower layers of the epidermis, induced by chronic long-term sun exposure.
• Clinical Presentation: Dry, rough, sandpaper-like, adherent scaly or crusted erythematous papules or plaques measuring 2 to 6 mm. They are frequently detected by tactile palpation before they are clearly visible, appearing on the face, scalp, ears, and hands of fair-skinned individuals.
• Prognosis & Action: Approximately 10% of untreated actinic keratoses progress into invasive Squamous Cell Carcinoma. Estheticians must never attempt to scrape, peel, or abrade an actinic keratosis; client must be referred to a dermatologist for cryosurgery or topical chemotherapeutic agents (such as 5-fluorouracil).

Basal Cell Carcinoma (BCC)

• Pathology: The most frequent form of human skin cancer, accounting for approximately 80% of all non-melanoma skin malignancies. It arises from the pluripotential stem cells of the stratum basale of the epidermis and hair follicle outer root sheath.
• Clinical Presentation: Classically manifests as a smooth, pearly, translucent or flesh-colored nodule with prominent, branching telangiectasias (dilated capillaries) on the surface, elevated rolled borders, and a central depression or ulceration that crusts and bleeds easily following minor trauma ("a sore that does not heal").
• Prognosis: Slow-growing with an extremely low rate of metastasis (<0.1%), but if left untreated, it is locally destructive, invading underlying muscle, cartilage, and bone.

Squamous Cell Carcinoma (SCC)

• Pathology: The second most common cutaneous malignancy, accounting for approximately 20% of skin cancers. It arises from the malignant transformation of keratinocytes in the stratum spinosum of the epidermis.
• Clinical Presentation: Presents as a firm, indurated, erythematous nodule or an elevated, rough, crusted, wart-like plaque with irregular borders. It frequently develops a persistent, non-healing central ulcer that bleeds easily. Common sites include the lower lip, ears, scalp, face, and dorsum of the hands.
• Prognosis: Faster-growing than BCC with a distinct capacity for metastasis to regional lymph nodes and distant internal organs if not excised early with clear surgical margins.

Malignant Melanoma

• Pathology: The most aggressive and lethal form of cutaneous neoplasm, accounting for only 1% to 2% of skin cancer cases but responsible for the vast majority (>75%) of skin cancer-related deaths. It originates from the malignant neoplastic transformation of melanocytes at the dermal-epidermal junction or within pre-existing dysplastic nevi.
• Clinical Presentation: Irregular, asymmetrical, darkly pigmented macules, plaques, or nodules displaying variegated coloration (shades of black, brown, red, white, or blue) with notched, scalloped borders.
• Prognosis: High propensity for rapid radial and vertical growth, early invasion into the vascular and lymphatic networks of the dermis, and widespread systemic metastasis to the lungs, liver, brain, and bones. Prognosis is directly dictated by the Breslow depth of invasion at the time of surgical excision.

---

2. The ABCDE Melanoma Screening Rule

The ABCDE criteria represents the gold-standard clinical screening mnemonic developed by the American Academy of Dermatology to assist health professionals and estheticians in identifying early suspicious characteristics of malignant melanoma:

The ABCDE Melanoma Screening Framework:
├── A = Asymmetry ──────────> One half of the lesion does not match the contralateral half
├── B = Border Irregularity ─> Edges are scalloped, notched, jagged, or poorly defined
├── C = Color Variation ────> Multiple variegated shades (black, dark brown, red, white, blue)
├── D = Diameter ───────────> Greater than 6 mm (approximate width of a pencil eraser)
└── E = Evolving ───────────> Lesion changes over time in size, shape, color, elevation, or symptoms

• A - Asymmetry: Draw an imaginary axis down the center of the lesion. If the two halves do not mirror each other in shape, outline, or elevation, the lesion is asymmetrical and suspicious.
• B - Border Irregularity: Benign nevi have smooth, continuous, circular or oval borders. Melanomas exhibit irregular, scalloped, notched, blurred, or jagged borders where the pigment fades unpredictably into surrounding skin.
• C - Color Variation: Benign moles typically display a uniform shade of light or dark brown. Suspicious lesions feature variegated, non-uniform coloration with multiple colors mingled within a single lesion (black, deep brown, tan, alongside areas of red, white, or slate-blue).
• D - Diameter: Pigmented lesions measuring greater than 6 millimeters (>6 mm) in diameter (approximately the size of a standard pencil eraser) warrant clinical evaluation, although early melanomas can occasionally present smaller.
• E - Evolving: The most critical clinical parameter. Any mole or lesion that is evolving—meaning it changes over time in size, shape, surface elevation, color, or develops new clinical symptoms (spontaneous bleeding, itching, tenderness, ulceration, or crusting)—is considered highly suspicious and requires immediate medical referral.

The "Ugly Duckling" Sign: In addition to ABCDE, clinicians look for the "ugly duckling" sign—a pigmented lesion on a client that looks distinctly different from all their other surrounding moles in color, size, or pattern.

---

3. Medical Contraindications & Client Referral Protocols

To ensure client safety and prevent disease transmission, estheticians must enforce strict screening boundaries:

Absolute Infectious Contraindications (Refuse / Postpone Treatment):

1. Bacterial Infections: Impetigo (contagious Staphylococcus or Streptococcus infection with vesicular eruptions and honey-colored crusts), active bacterial folliculitis, cellulitis.
2. Viral Infections: Active Herpes Simplex Virus outbreaks (vesicles on lips, perioral, or facial skin), Verruca vulgaris (warts), Molluscum contagiosum.
3. Fungal Infections: Tinea corporis (ringworm), Tinea barbae, active widespread fungal infections.
4. Parasitic Infestations: Scabies (Sarcoptes scabiei mite burrows), Pediculosis (head/body lice).
5. Open / Undiagnosed Wounds: Bleeding sores, unhealed surgical sutures, persistent oozing ulcers.

Professional Medical Referral Protocol:

When an esthetician discovers a suspicious lesion or absolute medical contraindication:

1. Do Not Alarm the Client: Maintain professional composure. Do not render a definitive medical diagnosis (e.g., never say "You have melanoma").
2. State Objective Observations: Use descriptive language (e.g., "I noticed a small dark mole on your temple that has an irregular border and mixed colors that I haven't seen before").
3. Explain Treatment Boundaries: Explain that for client safety, estheticians cannot perform exfoliation, chemical peels, or massage over undiagnosed lesions.
4. Issue Written Referral: Provide the client with written documentation noting the anatomical location of the lesion and strongly recommend a comprehensive evaluation by a board-certified dermatologist.
5. Document in Client Intake Record: Log the visual findings, the date, and the recommendation provided in the confidential client consultation chart.

---

Real-World Case Scenario: Identifying a Suspicious Pigmented Lesion

Scenario: During a routine anti-aging facial treatment on a 52-year-old male client in Traverse City, Michigan, the esthetician drapes the client and positions the 5-diopter magnifying lamp over the left temporal region. Near the hairline, the esthetician discovers an 8 mm pigmented lesion. The lesion is distinctly asymmetrical, with a notched, jagged upper border and variegated coloration consisting of dark charcoal-black, reddish-pink, and mottled brown areas. The client remarks, "My wife told me that spot has been growing and started bleeding whenever I dry off with a towel, but I figured it was just an age spot."

Analysis & Professional Protocol:

1. ABCDE Assessment: The lesion demonstrates all five high-risk criteria:
   • A: Asymmetrical contour.
   • B: Notched, jagged borders.
   • C: Variegated color (black, red, brown).
   • D: Diameter of 8 mm (exceeding the 6 mm threshold).
   • E: Evolving (growing in size with spontaneous bleeding upon minor friction).
2. Contraindication Protocol: The esthetician immediately halts any planned chemical peels, diamond microdermabrasion, steam, or mechanical friction near the left temporal zone.
3. Communication & Referral: The esthetician professionally addresses the client: "Mr. Davis, during our skin examination under the magnifying light, I observed a dark, irregular spot near your hairline that is wider than 6 mm, has uneven edges, and has been changing and bleeding. As a licensed esthetician, state regulations require that I avoid manipulating this area and advise you to have it evaluated promptly by a dermatologist for a biopsy. I am writing down the details and recommend scheduling an appointment this week."

---

Key Takeaways

• Precancer and cancers: actinic keratosis is precancerous; basal cell carcinoma, squamous cell carcinoma and malignant melanoma are the three malignancies to recognise as referral triggers.
• ABCDE: Asymmetry, Border irregularity, Colour variation, Diameter over about 6 mm, Evolution or change.
• Never diagnose: describe the observation, state that assessment is outside the esthetic scope, and recommend a physician or dermatologist.
• Absolute contraindication: no exfoliation, extraction, waxing or energy-based treatment over or adjacent to a suspicious lesion.